Healthcare

Thrombin Market is Likely to Reach US$690.1 mn by the end of 2025

Press Release

Global Thrombin Market: Snapshot

Thrombin is serine protease blood plasma protein which converts fibrinogen into soluble fibrin to catalyze blood coagulation process. Globally commercially available therapeutic thrombin products are derived from bovine source, human plasma and genetic recombination (recombinant). Thrombin JMI, Evithrom, Recothrom, Thrombin Mochida, etc. are few approved hemostatic products in the USA and Japan. Thrombin is used in several medical surgeries in management of uncontrolled bleeding. Thrombin is also used in diagnostic centers and clinics in various applications such as clotting factor tests, coagulation assays, and defibrination of blood or plasma. R&D applications of thrombin includes in several research activities such as in vitro study, coagulation research, protein-structure analysis, medical research and biochemical research. Bovine thrombin is referred as thrombin fractionated from bovine blood. Thrombostat was the first bovine blood-based thrombin product approved by the U.S. FDA in 1943. Currently, there are few bovine thrombin brands available in market such as Thrombin JMI, Thrombi-Pad, and BioTrombina. Generally, bovine-based thrombin products have a black box warning due to the risk of abnormal hemostasis.

Obtain Report Details @

https://www.transparencymarketresearch.com/thrombin-market.html

Demand for Bovine Thrombin to Rise at Considerably High Pace

Among the key product types, the bovine thrombin segment recorded surging demand and emerged as a key revenue contributor to the global thrombin market in 2016. TMR expects the global thrombin market to set sail on a growth path in response to the rising availability of bovine-based hemostatic brands such as Thrombin JMI. Besides this, the market will benefit from the rising adoption of bovine-based products in various research and diagnostic applications. Experts have also observed a spike in the recombinant thrombin uptake, which is attributed to lesser post-operative complications and safer hemostatic se in comparison to human and bovine thrombin.

Request for Sample Copy of Report @

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=19580

In terms of end user, the hospital segment held the dominant share of 56.2% in the global market in 2016. The rising hemostatic use of thrombin-based products during surgeries has fuelled the demand for thrombin in the hospitals segment. In addition, the market is likely to witness lucrative growth prospects in the diagnostic centers and clinics segment, which held a considerable share in the global market in 2016.

Request Report Brochure @

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=19580

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact Us

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: [email protected]
Website: www.transparencymarketresearch.com

Tags

Related Articles

Close